ADVANCED HEALTH LIMITED - Trading Statement

Trading Statement

ADVANCED HEALTH LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2013/059246/06)
(“the Company” or “Advanced Health”)
ISIN Code: ZAE000189049            JSE Code: AVL


TRADING STATEMENT


In terms of paragraph 3.4(b) of the Listings Requirements of the Johannesburg Stock Exchange, listed
companies are required to publish a trading statement as soon as they become reasonably certain that the
financial results for the next period to be reported on will differ by more than 20% from those of the previous
corresponding period.

Following the trading statement published on SENS on 8 June 2017, shareholders are advised that Advanced
Health expects to report a net loss after taxation attributable to the parent for the year ended 30 June 2017,
of R48.176 million compared to R18.311 million for the year ended 30 June 2016.

The loss per share will be 21.74 cents for the year ended 30 June 2017 compared to 8.26 cents per share for
the year ended 30 June 2016.

Headline loss for the year will be R48.202 million compared to the prior year headline loss of R17.767 million.
Accordingly, the headline loss per share will be 21.75 cents for the year ended 30 June 2017 compared to
8.02 cents per share for the year ended 30 June 2016.

The increase in losses are as anticipated and in accordance with the Company rolling out its known strategy
to become the leading provider of day hospitals in South Africa and Australia. In South Africa, the group now
consists of ten operational day hospitals and four in Australia. The company is starting to see an increase in
the number of patients treated and consequently turnover in both South Africa and Australia is increasing.

In July 2017, the Australian subsidiary of Advanced, Presmed Australia (PMA) acquired 100% of a one theatre
ophthalmic day hospital 25km north-west of Central Sydney. This is the fourth day hospital in the PMA group.
The acquired facility is accredited, licensed, has contracts with the major medical schemes and is well
positioned close to all ophthalmologists in the greater area. The acquisition is not categorisable in terms of
the JSE Listings Requirements.

The information in this trading statement has not been reviewed and reported on by the Company’s auditors.

The company’s results announcement for the year ended 30 June 2017 is expected to be published on or
about 30 August 2017.


Johannesburg
29 August 2017

Designated Advisor
Grindrod Bank Limited

Date: 29/08/2017 02:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.